George Koroneos


Mixed Criticism on Avandia Effectiveness

GSK's blockbuster diabetes drug Avandia was the subject of a number of studies this week offering good and bad news. But the company's big challenge is going to be FDA's advisory review panel set to meet in two short weeks.

Pfizer Pulls Leukemia Treatment

Pfizer was forced (voluntarily) to put the kibosh on a fast-tracked Wyeth drug after some not-so-favorable postmarket data. Was this a good catch or an endemic problem with expedited drugs?

Sanofi-Aventis Cuts 400 Jobs

Sales reps faced another round of layoffs last week as Sanofi-Aventis restructures its sales force due to looming generic competition and a dip in sales.

GSK and Pfizer to Discount Pneumonia Vaccines for the Poor

Proving that one good turn deserves another, Pfizer and GlaxoSmithKline announced that they would provide millions of doses of pneumonia vaccines to some of the world's most impoverished countries at massive discounts.